Early-stage Dupuytren's disease treatment; a promising next step?

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	e377-e378
Journal	The Lancet Rheumatology
Volume	4
Issue number	6
DOIs	https://doi.org/10.1016/S2665-9913(22)00128-X
Publication status	Published - 1 Jun 2022

Access to Document

10.1016/S2665-9913(22)00128-XLicence: Unspecified

Other files and links

Link to publication in Scopus

Cite this

@article{23ebcf7f9bd9402f8a6925ee60ec735a,

title = "Early-stage Dupuytren's disease treatment; a promising next step?",

author = "Ruud Selles",

year = "2022",

month = jun,

day = "1",

doi = "10.1016/S2665-9913(22)00128-X",

language = "English",

volume = "4",

pages = "e377--e378",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Early-stage Dupuytren's disease treatment; a promising next step?

AU - Selles, Ruud

PY - 2022/6/1

Y1 - 2022/6/1

UR - http://www.scopus.com/inward/record.url?scp=85130516027&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(22)00128-X

DO - 10.1016/S2665-9913(22)00128-X

M3 - Comment/Letter to the editor

C2 - 38293953

AN - SCOPUS:85130516027

SN - 2665-9913

VL - 4

SP - e377-e378

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 6

ER -